| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 1 security · passive | ||||||
|
Chemomab Therapeutics Ltd.
13G/A
GLTO · 36322Q107
|
1.2% |
8/10/2026
Event 8/10/2026
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.